Edwards-JenaValve deal 'soars over the bar set by Congress,' US FTC argues
MLex Summary: Edwards Lifesciences' proposed acquisition of JenaValve Technology is a brazen violation of America's cornerstone merger control law, the Clayton Act, the US Federal Trade Commission said in a memo...To view the full article, register now.
Already a subscriber? Click here to view full article